RGNX REGENXBIO Inc.
USHealthcareAs of 2026-07-10 16:00
Why RGNX matters now
REGENXBIO Inc. (RGNX) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.95 with -10.86% on the session and $721.2M in market capitalization; recent performance reads 1-month +37.81% and YTD -45.83%.
The latest financial table shown here is Q1 2026, with revenue of $6.4M, net income of $-90.1M, and EPS of $-1.72. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -58.6%.
The latest indexable market news headline is "REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes Bennett Jean filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
19.40
P/S
4.59
EV/EBITDA
-2.00
DCF Value
$-24.59
FCF Yield
-58.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-0.1%
Operating Margin
-292.3%
Net Margin
-330.2%
ROE
-232.5%
ROA
-84.8%
ROIC
-92.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.4M | $-90.1M | $-1.72 |
| Q4 2025 | $30.3M | $-67.1M | $-1.30 |
| FY 2025 | $170.4M | $-193.9M | $-3.76 |
| Q3 2025 | $29.7M | $-61.9M | $-1.20 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$19.17
Target (Median)
$17.00
Target Range
$12.00 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.03
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.